# Genetic Disorder Linked to Autism May Affect Tens of Thousands More Americans Than Previously Known
Phelan-McDermid syndrome, a rare genetic disorder strongly associated with autism spectrum disorder, appears far more prevalent than medical literature suggests. A new analysis estimates the condition affects roughly 1 in 7,300 people globally, translating to more than 45,000 Americans currently living with the disorder. The finding raises alarm about undiagnosed cases and the critical window closing as experimental treatments enter clinical trials.
Phelan-McDermid syndrome results from deletions or mutations in the SHANK3 gene on chromosome 22. The condition causes developmental delays, intellectual disability, autism features, and speech difficulties. Until now, researchers classified it as exceedingly rare, with estimates hovering around 1 in 15,000 to 1 in 50,000 people. The new prevalence data suggests these figures severely underestimate true occurrence.
The analysis identified a fundamental gap in disease detection. Genetic testing remains inconsistently applied across healthcare systems. Many patients with developmental delays and autism receive diagnoses of autism alone without the comprehensive genetic workup that would identify Phelan-McDermid syndrome as the underlying cause. This diagnostic blind spot means thousands of individuals never receive confirmation of their condition, preventing them from accessing disease-specific resources and potential treatments.
The timing proves critical. Several therapeutic approaches targeting SHANK3 deficiency and related cellular dysfunction have advanced into human trials. Researchers at major institutions now test drugs addressing synaptic dysfunction, a hallmark of Phelan-McDermid syndrome that also underlies many autism cases. Early intervention during development offers the best prospects for therapeutic benefit. Patients currently going undiagnosed miss windows when emerging treatments could provide the greatest impact.
The research team examined multiple datasets and genetic databases to reach their updated prevalence estimate. They found that cases detected through clinical genetic testing likely represent only a fraction of the true disease burden. Many individuals diagnosed with autism alone or idiopathic intellectual disability almost certainly carry SHANK3 variants without anyone identifying them.
Healthcare providers often fail to order targeted genetic testing when evaluating children with developmental disorders. Insurance coverage remains inconsistent. Genetic counseling resources vary widely by region. The path to diagnosis requires multiple specialist visits and sometimes years of investigation. Families frequently encounter skepticism about pursuing genetic testing once an autism diagnosis already exists, even though identifying the underlying genetic cause changes treatment planning and prognosis.
This discrepancy between actual and diagnosed prevalence carries immediate clinical consequences. Individuals with confirmed Phelan-McDermid syndrome qualify for specialized clinical trials and experimental therapies. They also access genetic counseling addressing family planning and inheritance risks. Extended family members may discover their own undiagnosed cases. Research into the disorder accelerates when patient numbers accurately reflect reality.
The findings should prompt healthcare systems to implement broader genetic screening protocols in developmental disability evaluation. Standard testing panels could include SHANK3 analysis alongside other common developmental disorder genes. Increased awareness among pediatricians, developmental specialists, and genetic counselors would drive earlier detection. Professional societies now face pressure to update guidelines recommending when genetic testing merits consideration in autism and developmental delay cases.
As treatments targeting the biological mechanisms underlying Phelan-McDermid syndrome move toward clinical availability, the stakes for early identification grow higher. Thousands of Americans currently remain unaware they carry mutations causing their developmental challenges. Closing this diagnostic gap requires systemic changes in how medicine approaches genetic testing in neurodevelopmental conditions.